Idoroenyi Amanam, MD

Idoroenyi Amanam, MD, discusses the efficacy of first-line luspatercept vs erythropoiesis-stimulating agents in real-world patients with lower-risk MDS.

Idoroenyi Amanam, MD, discusses the JAK inhibitors he most commonly reaches for in his clinical practice when treating patients with myelofibrosis.

Idoroenyi Amanam, MD, discusses potential treatment advancements in myelofibrosis and highlights the use of stem cell transplant in this disease.

Idoroenyi Amanam, MD, discusses criteria for selecting patients with myelofibrosis who may benefit from JAK inhibitors.

Idoroenyi Amanam, MD, discusses the myelofibrosis treatment paradigm, highlighting patients who may derive the most benefit for JAK inhibitor treatment.

Idoroenyi Amanam, MD, discusses adverse effects associated with JAK inhibitors in myelofibrosis.